Conclusions
reductions in blood NE
Brensocatib demonstrated dose dependent reductions in blood NE and sputum NSP activity in the WILLOW study. These data suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients.